LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

Начало・Списък с акции・Certara Inc

Certara Inc

Отворен

СекторЗдравеопазване

8.85 -2.75

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.56

Максимум

9.19

Ключови измерители
By Trading Economics
Приходи	3.5M 1.5M
Продажби	46K 105M
P/E Средно за сектора	129.857 77.671
EPS	0.14
Марж на печалбата	1.458
Служители	1,487
EBITDA	-6.5M 23M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+42.78% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-432M 1.4B
Предишно отваряне	11.6
Предишно затваряне	8.85

Настроения в новините

By Acuity

94%

356 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

11.27 / 12.79 Подкрепа & съпротива

Certara Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.12.2025 г., 23:58 ч. UTC

Придобивния, сливания и поглъщания

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11.12.2025 г., 23:56 ч. UTC

Печалби

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11.12.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11.12.2025 г., 21:50 ч. UTC

Печалби

Costco Same-Store Sales, Membership Fees Rose in 1Q

11.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.12.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11.12.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11.12.2025 г., 23:31 ч. UTC

Печалби

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11.12.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11.12.2025 г., 22:35 ч. UTC

Печалби

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11.12.2025 г., 22:30 ч. UTC

Печалби

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11.12.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11.12.2025 г., 22:05 ч. UTC

Печалби

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11.12.2025 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

11.12.2025 г., 21:39 ч. UTC

Печалби

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11.12.2025 г., 21:39 ч. UTC

Печалби

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11.12.2025 г., 21:38 ч. UTC

Печалби

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11.12.2025 г., 21:37 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11.12.2025 г., 21:37 ч. UTC

Пазарно говорене

Broadcom Sees AI Revenue Doubling -- Market Talk

11.12.2025 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Dexus Aiming for Long-Term Holding of A$50M in Fund

11.12.2025 г., 21:28 ч. UTC

Пазарно говорене

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Dexus: Third Party Investors to Contribute Remainder

11.12.2025 г., 21:27 ч. UTC

Придобивния, сливания и поглъщания

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11.12.2025 г., 21:26 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11.12.2025 г., 21:25 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Сравнение с други в отрасъла

Ценова промяна

Certara Inc Прогноза

Ценова цел

By TipRanks

42.78% нагоре

12-месечна прогноза

Среден 13.25 USD 42.78%

Висок 16 USD

Нисък 9 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Certara Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Certara Inc през последните 3 месеца.

Техническа оценка

By Trading Central

11.27 / 12.79Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

356 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.